Enlitic Strengthens Partnership with GE Healthcare Through Expanded Engagement.
Enlitic, Inc. (ASX: ENL) has unveiled a major expansion of its collaboration with GE Healthcare, signalling deeper integration and continued confidence in its medical imaging data solutions. The newly added scope builds on the current migration program and is set to generate roughly US$1 million in additional one-off revenue over the next year. This move broadens the application of Enlitic’s technology within GE Healthcare and reinforces the strategic importance of the relationship for both companies.
To meet the demands of this expanded project, Enlitic will temporarily shift internal resources, leading to updated migration timelines that GE Healthcare has reviewed and accepted. Both teams are coordinating closely to optimise scheduling and maintain delivery quality across all contracted milestones. While advancing this initiative, Enlitic remains committed to supporting partners and stakeholders and will engage with customers at the upcoming RSNA Conference in Chicago to showcase further developments.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Enlitic Strengthens Partnership with GE Healthcare Through Expanded Engagement.
Enlitic, Inc. (ASX: ENL) has unveiled a major expansion of its collaboration with GE Healthcare, signalling deeper integration and continued confidence in its medical imaging data solutions. The newly added scope builds on the current migration program and is set to generate roughly US$1 million in additional one-off revenue over the next year. This move broadens the application of Enlitic’s technology within GE Healthcare and reinforces the strategic importance of the relationship for both companies.
To meet the demands of this expanded project, Enlitic will temporarily shift internal resources, leading to updated migration timelines that GE Healthcare has reviewed and accepted. Both teams are coordinating closely to optimise scheduling and maintain delivery quality across all contracted milestones. While advancing this initiative, Enlitic remains committed to supporting partners and stakeholders and will engage with customers at the upcoming RSNA Conference in Chicago to showcase further developments.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au.au